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Introduction {#sec005}
============

Prostate cancer is one of the most common malignancy in men, and it is a major cause of morbidity and kills approximately 27,000 people per year in the United States. \[[@pone.0230290.ref001]\] Recently, the incidence of prostate cancer is increasing in most countries, including Asia. \[[@pone.0230290.ref002]\] Although there are various treatment options for prostate cancer, radical prostatectomy is recommended for localized prostate cancer patients with a life expectancy \> 10 years as a first-line treatment. \[[@pone.0230290.ref002]\] Robot-assisted radical prostatectomy (RARP) has been widely adopted as a standard procedure for clinically localized prostate cancer worldwide due to less blood loss, lower blood transfusion rate, and less hospitalization stay compared with open radical prostatectomy. \[[@pone.0230290.ref002]\] Unfortunately, recurrence of prostate cancer after surgery increases postoperative morbidity and mortality. \[[@pone.0230290.ref001]\] Surgical intervention itself may result in neuroendocrine and metabolic changes which may impair cell-mediated immunity and activation of circulating tumor cell implantation. \[[@pone.0230290.ref003]\] This potential combination of impaired immune responses and circulating cancer cell seeding enhances the susceptibility of patients undergoing cancer surgery to the development of postoperative recurrence or metastasis, and is associated with poor prognosis.

Recently, the potential role of anesthetic techniques in the process of postoperative recurrence or metastasis formation has attracted attention. \[[@pone.0230290.ref003]\] Experimental data showed that different anesthetics might affect the immune system in different paths. \[[@pone.0230290.ref004]--[@pone.0230290.ref009]\] Research has shown that volatile anesthetics (VAs) are pro-inflammatory and might affect immune processes, which might increase the incidence of postoperative recurrence or metastasis. \[[@pone.0230290.ref008]--[@pone.0230290.ref012]\] However, propofol seemed to reduce tumor proliferation, invasion, and migration and then to decrease the risk of recurrence or metastasis in humans and mice. \[[@pone.0230290.ref006],[@pone.0230290.ref011]--[@pone.0230290.ref014]\]

Until now, very few studies have compared the effects of the use of desflurane versus propofol anesthesia on patient outcomes after RARP. We hypothesized that patients under desflurane anesthesia may have poorer overall survival/postoperative biochemical recurrence (primary/secondary hypothesis) than patients under propofol anesthesia as our previous colon cancer and hepatocellular carcinoma studies. \[[@pone.0230290.ref015],[@pone.0230290.ref016]\] Thus, we conducted a retrospective cohort study to inspect whether the type of anesthesia, desflurane versus propofol was associated with patient survival and postoperative biochemical recurrence (BCR) following RARP.

Methods {#sec006}
=======

Study design and setting {#sec007}
------------------------

This retrospective cohort study was performed at the Tri-Service General Hospital, Taipei, Taiwan, Republic of China.

Participants and data sources {#sec008}
-----------------------------

The ethics committee of the Tri-Service General Hospital approved this retrospective study and waived the need for informed consent (TSGHIRB No: 1-108-05-119). The information was retrieved from the electronic database and medical records of TSGH. From January 2008 and December 2018, 631 cases with an American Society of Anesthesiologists (ASA) score of II--III who had received elective RARP for tumor-node-metastasis (TNM) of stage I--IV prostate cancer under propofol anesthesia (n = 266) or desflurane anesthesia (n = 365) were eligible for analysis. The type of anesthesia was decided by the anesthesiologist's personal preference. The exclusion criteria were propofol anesthesia combined with VAs or regional analgesia, desflurane anesthesia combined with regional analgesia, incomplete data, age \< 20 years. And then, 26 cases were excluded ([Fig 1](#pone.0230290.g001){ref-type="fig"}).

![Flow diagram detailing the selection of patients included in the retrospective analysis.\
26 patients were excluded due to combined propofol anesthesia with inhalation anesthesia or regional analgesia, desflurane anesthesia combined with regional analgesia, incomplete data, age \< 20 years.](pone.0230290.g001){#pone.0230290.g001}

No medication was used before the anesthesia induction. Standard monitoring systems, including electrocardiography (lead II), noninvasive blood pressure testing, pulse oximetry, end-tidal carbon dioxide measurement, and direct radial arterial blood pressure were performed in each case. Anesthesia was induced using fentanyl, propofol, and cisatracurium or rocuronium in all cases.

Anesthesia was maintained with target-controlled infusion (Fresenius Orchestra Primea; Fresenius Kabi AG, Bad Homburg, Germany) using propofol at an effect-site concentration of 3--4 μg/mL in Fi[o]{.smallcaps}2 of 100% oxygen at a flow rate of 300 mL/min in the propofol group. The desflurane vaporizer was set between 4% and 10% in 100% oxygen at a flow of 300 mL/min in a closed breathing system in the desflurane group. Repetitive bolus injections of fentanyl and cisatracurium or rocuronium were used as needed during surgery. \[[@pone.0230290.ref015],[@pone.0230290.ref016]\] Desflurane or maintenance of the effect-site concentration with target-controlled infusion using propofol was adjusted downward and upward by 0.5--2% or 0.2--0.5 μg/mL, respectively, when needed based on the hemodynamics. The level of end-tidal carbon dioxide was kept at 35--45 mmHg by adjusting the ventilation rate with volume control model with tidal volume 6--8 mg/kg and kept a maximum airway pressure \< 30 cm H~2~O. After surgery, all cases were transferred to the postanesthesia care unit for subsequent care.

Variables {#sec009}
---------

We retrospectively gathered the following patient data: anesthetic technique; time since the earliest included patient, which served as a surrogate of the calendar year; calendar period; sex; age at the time of surgery; and preoperative serum prostate specific antigen (PSA) values. For preoperative PSA levels, patients were grouped according to whether their PSA levels were \> 10 or ≤ 10 ng/mL, because a PSA level ≤ 10 ng/mL was associated with better prognosis in prostate cancer. \[[@pone.0230290.ref017]\] We used the Charlson Comorbidity Index (CCI) to predict the 10-year survival in patients with multiple comorbidities. The preoperative functional capacity was assessed in metabolic equivalents (METs). Because the cardiac and long-term risks increase in patients with a functional capacity of \< 4 METs during most normal daily activities, \[[@pone.0230290.ref018]\] and patients were grouped according to whether the value was ≥ 4 METs or \< 4 METs. We also used the Clavien--Dindo classification, scaled from 0 (no complication) to V (most complications), to grade surgical complications. Other data included the ASA physical status score (ranging from I, indicating the lowest morbidity, to V, indicating the highest morbidity); TNM stage of the primary tumor; histological grade of the tumor (low risk: Gleason grade ≤ 6; medium risk: Gleason = 7; high risk: Gleason \> 7) \[[@pone.0230290.ref017]\]; tumor size; intraoperative blood transfusion; postoperative chemotherapy; postoperative radiation therapy; postoperative androgen deprivation therapy; presence of postoperative BCR (defined as two consecutive rises in serum PSA levels ≥ 0.2 ng/mL at any time postoperatively) \[[@pone.0230290.ref019]\]; and presence of postoperative metastases. Because these variables have been shown or posited to affect patient outcomes, they were chosen as potential covariates.

Statistical methods {#sec010}
-------------------

The primary end point was overall survival, which was compared between the propofol and desflurane groups. The survival time was defined as the interval between the date of surgery and the date of death or July 05, 2019, for those who were censored. All data are presented as mean ± standard deviation (SD) or number (percentage).

Mortality rates and patient characteristics were compared between the groups treated with the different anesthetics using Student's *t* test, or the chi-square test. The survival according to the anesthetic technique was depicted visually in a Kaplan--Meier survival curve. The association between the type of anesthesia (propofol or desflurane) and survival was analyzed by the Cox proportional-hazards model with and without adjustment for the abovementioned variables as well as surgeons (n = 9). Though no significant interactions with the two anesthetic techniques (propofol or desflurane) were found, due to more than 80% patients with TNM II+III, we also performed subgroup analyses for TNM stage as well as postoperative BCR.

Propensity score (PS) matching with IBM SPSS Statistics 22.0 was used to select for the most similar PSs for preoperative variables (with calipers set at 0.2 SD of the logit of the PS) across each anesthesia: propofol or desflurane in a 1:1 ratio, to make sure the comparability between propofol and desflurane anesthesia before the surgery. Two-tailed *P*-values less than 0.05 were considered statistically significant.

Results {#sec011}
=======

The patients' and treatment characteristics were shown in [Table 1](#pone.0230290.t001){ref-type="table"}. Desflurane anesthesia had longer time since the earliest included patient compared with propofol anesthesia (5.3 ± 3.0 *vs* 4.8 ± 2.4 years; *P* = 0.014). The calendar period was significantly different between the two anesthetic techniques (*P* \< 0.001). Age, CCI, preoperative functional status, ASA score, TNM stage of the prostate cancer, preoperative PSA level, tumor size, histological grade of the prostate cancer, grade of surgical complications, need for intraoperative blood transfusion, and the use of postoperative radiation therapy or androgen deprivation therapy were not significantly different between the two anesthetic techniques ([Table 1](#pone.0230290.t001){ref-type="table"}). In addition, no patient was given postoperative chemotherapy.

10.1371/journal.pone.0230290.t001

###### Patients' and treatment characteristics for overall group and matched group after propensity scoring.

![](pone.0230290.t001){#pone.0230290.t001g}

  Variables                                                     Overall Patients   Matched Patients                                                 
  ------------------------------------------------------------- ------------------ ------------------ --------- ------------ ------------ --------- -------
  Time since the earliest included patient (years), Mean (SD)   4.8 (2.4)          5.3 (3.0)          0.014     4.8 (2.4)    4.3 (2.5)    0.045     0.177
  Calendar period, n (%)                                                                              \<0.001                             0.080     0.133
   2009--12                                                     92 (35)            125 (34)                     92 (35)      116 (44)               
   2013--15                                                     110 (41)           97 (27)                      110 (42)     89 (34)                
   2016--18                                                     64 (24)            143 (39)                     62 (24)      59 (22)                
  Age (yr), mean (SD)                                           65.3 (6.5)         66.4 (7.2)         0.066     65.3 (6.5)   66.3 (7.4)   0.118     0.136
  PSA                                                                                                 0.604                               0.254     0.119
   ≤ 10                                                         143 (54)           205 (56)                     141 (53)     155 (59)               
   \> 10                                                        123 (46)           160 (44)                     123 (47)     109 (41)               
  Charlson comorbidity index, mean (SD)                         4.1 (0.70)         4.2 (0.78)         0.164     4.1 (0.70)   4.2 (0.79)   0.242     0.108
  Functional status, n (%)                                                                            0.232                               0.549     0.131
   \< 4 METs                                                    22 (8)             42 (12)                      22 (8)       27 (10)                
   ≥ 4 METs                                                     244 (92)           323 (89)                     242 (92)     234 (90)               
  ASA, n (%)                                                                                          0.232                               0.549     0.131
   Lower risk                                                   244 (92)           323 (89)                     242 (92)     234 (90)               
   Higher risk                                                  22 (8)             42 (12)                      22 (8)       27 (10)                
  TNM stage of primary tumor, n (%)                                                                   0.563                               0.045     0.173
   I                                                            44 (17)            65 (18)                      43 (16)      51 (19)                
   II                                                           197 (75)           274 (75)                     196 (74)     202 (77)               
   III                                                          25 (9)             26 (7)                       25 (10)      11 (4)                 
  Tumor grade (Gleason grade)                                                                         0.145                               0.178     0.011
   Low risk (Gleason grade ≤ 6)                                 36 (14)            45 (12)                      34 (13)      24 (9)                 
   Medium risk (Gleason = 7)                                    101 (38)           167 (46)                     101 (38)     119 (45)               
   High risk (Gleason \> 7)                                     129 (49)           153 (42)                     129 (49)     121 (46)               
  Tumor size (cm), mean (SD)                                    1.6 (0.89)         1.5 (0.83)         0.169     1.6 (0.89)   1.6 (0.87)   0.419     N/A
  Intraoperative blood transfusion, n (%)                       10 (4)             8 (2)              0.354     10 (4)       6 (2)        0.446     N/A
  Grade of surgical complications, n (%)                                                              0.975                               1.000     N/A
   0                                                            257 (97)           354 (97)                     255 (97)     256 (97)               
   I + II                                                       9 (3)              11 (3)                       9 (3)        8 (3)                  
  Postoperative radiation therapy, yes, n (%)                   32 (12)            50 (14)            0.620     32 (12)      34 (13)      0.895     N/A
  Postoperative ADT, yes, n (%)                                 42 (16)            55 (15)            0.892     42 (16)      46 (17)      0.726     N/A
  Postoperative biochemical recurrence, n (%)                   2 (1)              13 (4)             0.043     2 (1)        12 (5)       0.015     N/A
  All-cause mortality, n (%)                                    2 (1)              24 (7)             0.001     2 (1)        21 (8)       \<0.001   N/A
  Cancer mortality, n (%)                                       0 (0)              5 (1)              0.073     0 (0)        4 (2)        0.055     N/A

PSA: prostate specific antigen; METs: Metabolic equivalents; ASA: American Society of Anesthesiologists; TNM: tumor-node-metastasis; ADT: androgen deprivation therapy; SMD: standardized mean differences; N/A: not applicable.

[Table 1](#pone.0230290.t001){ref-type="table"} also showed that all-cause mortality rate was significantly lower in the propofol anesthesia (1.0%) than in the desflurane anesthesia (7.0%) during follow-up (*P* = 0.001). However, the cancer-specific mortality rate was insignificantly different between the two anesthetic techniques during follow-up (*P* = 0.073). A lower percentage of patients in the propofol anesthesia (1.0%) exhibited postoperative BCR compared with the desflurane anesthesia (4.0%; *P* = 0.043). There was no postoperative metastasis in the two groups. Kaplan--Meier survival curves for the two anesthetic techniques are shown in [Fig 2A](#pone.0230290.g002){ref-type="fig"}.

![(A) Overall survival curves from the date of surgery by anesthesia type. (B) Overall survival curves from the date of surgery by anesthesia type after propensity score matching.](pone.0230290.g002){#pone.0230290.g002}

The overall mortality risk associated with the use of propofol and desflurane during prostate cancer surgery was reported in [Table 2](#pone.0230290.t002){ref-type="table"}. Overall survival from the date of surgery grouped according to the anesthetic technique and other variables were compared individually in a univariable Cox model and subsequently in a multivariable Cox regression model ([Table 2](#pone.0230290.t002){ref-type="table"}). Patients with propofol anesthesia exhibited overall survival compared to those with desflurane anesthesia (overall survival 99.0% versus 93.0%, respectively; the crude hazard ratio (HR) was 0.11 (95% confidence interval (CI), 0.03--0.47; *P* = 0.003). This finding did not change substantially in the multivariable analyses after adjustment for those significant variables in the univariable analyses and 9 surgeons (HR, 0.12; 95% CI, 0.03--0.54; *P* = 0.006). After the multivariable analysis, a higher preoperative PSA level was another variable that was identified that significantly increased the mortality risk ([Table 2](#pone.0230290.t002){ref-type="table"}). Kaplan--Meier survival curves for the two anesthetic techniques after PS matching are shown in [Fig 2B](#pone.0230290.g002){ref-type="fig"}.

10.1371/journal.pone.0230290.t002

###### Cox proportional hazards regression for mortality: Univariable and multivariable models for overall patients.

![](pone.0230290.t002){#pone.0230290.t002g}

                                                   Univariable          Multivariable                       
  ------------------------------------------------ -------------------- --------------- ------------------- -------
  Anesthesia, Propofol (ref: Desflurane)           0.11 (0.03--0.47)    0.003           0.12 (0.03--0.54)   0.006
  Time since the earliest op (yr)                  1.24 (0.96--1.60)    0.095                               
  Age (yr)                                         1.13 (1.06--1.22)    0.001           1.05 (0.87--1.28)   0.604
  PSA \>10 (ref: ≤ 10)                             5.50 (2.07--14.6)    0.001           4.89 (1.74--13.7)   0.003
  Charlson comorbidity index                       2.81 (1.50--5.25)    0.001           1.54 (0.31--7.62)   0.600
  Functional status, ≥4 METs (ref: \<4 METs)       0.27 (0.10--0.72\_   0.009                               
  ASA III, (ref: II)                               3.74 (1.40--10.0)    0.009           0.77 (0.17--3.53)   0.739
  TNM stage of primary tumor (ref: I)                                                                       
   II                                              1.28 (0.38--4.31)    0.690                               
   III                                             1.64 (0.27--9.86)    0.587                               
  Tumor grade (ref: low+ medium risk)                                                                       
   High risk                                       0.92 (0.41--2.06)    0.838                               
  Tumor size (cm)                                  1.10 (0.79--1.54)    0.572                               
  Intraoperative blood transfusion (ref: no)       5.12 (1.75--14.9)    0.003           1.53 (0.28--8.20)   0.623
  Grade of surgical complications (ref: 0)                                                                  
   I+II                                            5.91 (2.21--15.8)    \<0.001         2.14 (0.40--11.4)   0.374
  Postoperative radiation therapy (ref: no)        1.36 (0.54--3.42)    0.510                               
  Postoperative ADT (ref: no)                      2.42 (1.08--5.41)    0.032           1.58 (0.65--3.89)   0.315
  Postoperative biochemical recurrence (ref: no)   8.84 (3.31--23.6)    \<0.001                             

Adjusted-HRs were adjusted by those variables were significant in the univariable analyses and surgeons (n = 9). Functional status was excluded from the multivariable due to it was highly correlated with ASA. Postoperative biochemical recurrence was another outcome, therefore, it was also not included. PSA: prostate specific antigen; METs: Metabolic equivalents; ASA: American Society of Anesthesiologists; TNM: tumor-node-metastasis; ADT: androgen deprivation therapy.

We used the PS from the logistic regression to adjust the baseline characteristics and the choice of therapy between the two anesthetic techniques due to the significant differences in baseline characteristics between the two anesthetic techniques. Two hundred sixty-four pairs were formed after matching ([Table 1](#pone.0230290.t001){ref-type="table"}). Patient characteristics and prognostic factors of prostate cancer were insignificantly different between the matched groups.

Subgroup analyses for TNM stage and disease progression {#sec012}
-------------------------------------------------------

In the nonstratified analysis, patients with propofol anesthesia showed better survival than those with desflurane; the crude HR was 0.11 (95% CI, 0.03--0.47; *P* = 0.003), the PS-adjusted HR was 0.12 (95% CI, 0.03--0.49; *P* = 0.004), and the PS-matched HR was 0.11 (95% CI, 0.03--0.48; *P* = 0.003) ([Table 3](#pone.0230290.t003){ref-type="table"}).

10.1371/journal.pone.0230290.t003

###### Subgroup analyses for TNM stage and disease progression.

![](pone.0230290.t003){#pone.0230290.t003g}

  Stratified variable       Anaesthesia           Crude-HR (95% CI)        *P* value   *P* value (interaction)   PS adjusted-HR (95% CI)   *P* value           PS matched-HR (95% CI)   *P* value
  ------------------------- --------------------- ------------------------ ----------- ------------------------- ------------------------- ------------------- ------------------------ -------------
  **Nonstratified**         Desflurane            1.00                     0.003                                 1.00                                          1.00                     
  Propofol                  0.11 (0.03--0.47)                                          0.12 (0.03--0.49)         0.004                     0.11 (0.03--0.48)   0.003                    
  **TNM stage**                                                                        0.926                                                                                            
   TNM: I                                         (cannot converage)                                             (cannot converage)                            (cannot converage)       
   TNM: II+III              Desflurane            1.00                                                           1.00                                          1.00                     
  **Disease progression**   Propofol              0.13 (0.03--0.55) 1.00   0.005                                 0.13 (0.03--0.57) 1.00    0.006               0.13 (0.03--0.57) 1.00   0.007 0.038
   BCR                      Desflurane Propofol   0.20 (0.05--0.91)        0.037                                 0.20 (0.04--0.88)         0.033               0.20 (0.05--0.91)        

HR = hazard ratio; PS = propensity score; TNM = tumour--node--metastasis; BCR: biochemical recurrence.

Although the PS matching showed that propofol anesthesia provided better outcomes in TNM II+III patients (HR, 0.13; 95% CI, 0.03--0.57; *P* = 0.007), there was no significant interaction between the type of anesthesia and TNM stage (*P* = 0.926) ([Table 3](#pone.0230290.t003){ref-type="table"}).

Patients with propofol anesthesia had less postoperative BCR than those with desflurane; the crude HR was 0.20 (95% CI, 0.05--0.91; *P* = 0.037), the PS-adjusted HR was 0.20 (95% CI, 0.04--0.88; P = 0.033), and the PS-matched HR was 0.20 (95% CI, 0.05--0.91; *P* = 0.038).

In summary, patients with desflurane anesthesia had more significant disease progression (such as postoperative BCR) than those with propofol anesthesia.

Discussion {#sec013}
==========

The major findings in the present study are that propofol anesthesia in RARP improves survival and reduces postoperative BCR compared with desflurane anesthesia. The results were consistent with our previous reports demonstrating that propofol anesthesia was related to better survival and a lower incidence of postoperative recurrence or metastasis compared with desflurane anesthesia in colon cancer, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma surgery. \[[@pone.0230290.ref015],[@pone.0230290.ref016],[@pone.0230290.ref020],[@pone.0230290.ref021]\] By contrast, there were retrospective studies reporting insignificant differences in overall survival between the use propofol and VAs in surgery for breast cancer, lung cancer. \[[@pone.0230290.ref011],[@pone.0230290.ref022],[@pone.0230290.ref023]\] To our best knowledge, there are very few researches of the effects of the propofol and VAs in patients undergoing prostate cancer surgery, and further investigations are needed.

In the current study, we also showed that the overall postoperative BCR was 2.4%, and the postoperative BCR in the matched propofol group (1.0%) was less than in the matched desflurane group (5.0%) after RARP (*P* = 0.015). The result was consistent with Coughlin et al., who reported that postoperative BCR of prostate cancer occurs in 2.5% (4/157) of patients at a median follow up of 24 months after RARP. \[[@pone.0230290.ref024]\] In this study, we found that a higher preoperative PSA level was associated with poor survival after prostate cancer surgery, as have been observed previously. \[[@pone.0230290.ref017],[@pone.0230290.ref025]\] However, previous data indicated that considerable number of men had prostate cancer despite being within normal PSA range. Importantly, many of these patients were later found to have high grade histology. \[[@pone.0230290.ref026]\] Therefore, further investigation is necessary for the relationship between PSA or other biomarkers and prognosis of prostate cancer.

The perioperative stress induced by surgery leads to metabolic and neuroendocrine changes that result in significant depression of cell mediated immunity. \[[@pone.0230290.ref003]\] This can result in the emergence of micro-seed tumor cells during surgery, which can avoid host immune surveillance, and eventually result in tumor recurrence or metastasis. \[[@pone.0230290.ref003]\] The preclinical data showed that different anesthetic techniques or anesthetics might influence the immune system in different ways \[[@pone.0230290.ref004]--[@pone.0230290.ref009]\] and affect risks of cancer recurrence or metastasis or the cancer patient's survival. \[[@pone.0230290.ref006],[@pone.0230290.ref008]--[@pone.0230290.ref011]\] Postoperative biochemical recurrence has impacts on patient prognosis following prostate cancer surgery; thus, studies on prostate cancer have focused on searching paths to ameliorate overall patient survival via reducing them. \[[@pone.0230290.ref001],[@pone.0230290.ref027]\] In addition, Biki et al. \[[@pone.0230290.ref001]\] reported that epidural anesthesia/analgesia was associated with less risk of biochemical cancer recurrence in patients undergoing radical prostatectomy. However, Wuethrich et al. \[[@pone.0230290.ref028]\] showed that epidural analgesia did not reduce the risk of biochemical cancer recurrence or improve survival following open radical prostatectomy, and we did not routinely perform regional anesthesia/analgesia in RARP in our hospital.

Data from human prostate cancer cell lines supported the influence of propofol on prostate cancer cell growth and survival via reducing hypoxia-inducible factor (HIF)-1α expression. \[[@pone.0230290.ref029]--[@pone.0230290.ref030]\] Qian et al. \[[@pone.0230290.ref029]\] reported that propofol might inhibit prostate cancer progression and metastasis via decreasing HIF-1α expression and reversing hypoxia-induced epithelial-mesenchymal transition by suppressing HIF-1α. Huang et al. \[[@pone.0230290.ref030]\] showed that propofol reduced HIF-1α expression in prostate cancer cells. Upregulation of HIF was associated with a poor prognosis in colorectal cancers study. \[[@pone.0230290.ref031]\] In addition, HIF-1α was overexpressed in pancreatic cancer, \[[@pone.0230290.ref032]\] and a knockout of HIF-1α suppressed the metastasis of pancreatic cancer. \[[@pone.0230290.ref033]\] By contrast, previous researches showed that isoflurane had deleterious effects on the upregulation of HIF and stimulated angiogenesis in prostate and renal cancer cells. \[[@pone.0230290.ref030],[@pone.0230290.ref034]\] Taken together, these limited reports suggested that the administration of isoflurane \[[@pone.0230290.ref003],[@pone.0230290.ref030]\] or sevoflurane \[[@pone.0230290.ref003],[@pone.0230290.ref011],[@pone.0230290.ref012]\] may stimulate tumor cell growth, whereas propofol had a beneficial effect by suppressing tumor cell growth. \[[@pone.0230290.ref003],[@pone.0230290.ref011],[@pone.0230290.ref012]\] However, to our knowledge, the mechanism by which desflurane anesthesia influences the recurrence or metastasis of prostate cancer remains unknown. In addition, Tatsumi et al. \[[@pone.0230290.ref035]\] revealed that propofol suppressed nuclear androgen receptor protein levels, and inhibited androgen receptor transcriptional activity and proliferation in prostate cancer cells. These findings suggest that propofol may be a useful drug for treating prostate cancer, though further clinical studies are needed.

In this study, we showed that all-cause mortality was 4.1% after RPAP. In the matched groups, all-cause mortality and cancer-specific mortality were 4.4% and 0.8%, respectively. The result was similar with a previous study reporting that the all-cause mortality was 3.9%. \[[@pone.0230290.ref036]\] However, the cancer-specific mortality was lower than previous reports (1.7% and 4.3%). \[[@pone.0230290.ref037],[@pone.0230290.ref038]\] This might be due to the higher surgical volume at our center and higher level of experience because we excluded patients from the learning curve period of the first two years of surgery performed by our teams. \[[@pone.0230290.ref039],[@pone.0230290.ref040]\]

There were some limitations in the current study. First, it was retrospective and the 631 patients were not randomly allocated. Patient characteristics such as time since the earliest included patient and calendar period differed significantly between the groups, and we conducted PS matching to deal with this issue, and PS matching may minimize confounding in this observational study. \[[@pone.0230290.ref041]\] However, the small groups for propensity matching may influence the rigorousness of the statistical significance in our study. Fortunately, regardless the analytic approaches were applied, the point estimates and significances of relative risk of propofol versus desflurane were similar. Further prospective multi-center study is warranted. Second, different VAs may have different effects on prostate cancer. We analyzed only desflurane anesthesia because it is the most frequently used VA in our hospital. Third, we did not routinely use nonsteroidal anti-inflammatory drugs during prostate cancer surgery in our hospital, because of the risk of life-threatening complications such as peptic ulceration \[[@pone.0230290.ref042]\], and nonsteroidal anti-inflammatory drugs were not associated with prostate cancer survival. \[[@pone.0230290.ref043]\] Fourth, intraoperative opioids administration was associated with an increased risk of cancer recurrence after prostate cancer surgery, \[[@pone.0230290.ref044]\] but information about opioid use, especially for postoperative pain control, was incomplete in the medical records used in our study. However, we presumed there was no significant difference between the two anesthetic techniques in the use of intraoperative opioids in the patients included in our current study as previous laparoscopic surgery research. \[[@pone.0230290.ref045]\] Fifth, previous studies reported that high hospital or surgeon volumes were significantly associated with positive patient outcomes in prostate cancer surgery. \[[@pone.0230290.ref046]--[@pone.0230290.ref047]\] We conducted the surgeon analysis (n = 9) and the result showed that, in our high volume surgery center, the postoperative outcome was not affected by which surgeon performed the procedure ([Table 2](#pone.0230290.t002){ref-type="table"}). Finally, the anesthesiologists chose the type of anesthesia, which may have been subject to original selection bias between propofol and desflurane anesthesia. However, Jaeger et al. \[[@pone.0230290.ref048]\] concluded that anesthesiologist volumes were not associated with postoperative mortality or long-term survival after radical cystectomy for bladder cancer. Therefore, the postoperative outcome might not affect by anesthesiologists in RAPR in our high anesthesiologist volume hospital.

In conclusion, propofol anesthesia in RARP was associated with improved survival and lower risk of postoperative BCR compared with desflurane. Further investigations are needed to inspect the influences of propofol anesthesia on patient outcomes of prostate cancer surgery.

The authors thank the Cancer Registry Group of Tri-Service General Hospital for the clinical data support.
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Dear Dr.Zhi-Fu Wu

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
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ACADEMIC EDITOR: I would appreciate if you reply carefully to the reviewers\' comments.

==============================

We would appreciate receiving your revised manuscript by Mar 28 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Ehab Farag, MD FRCA FASA

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This study investigates the effect of anesthetic technique on survival in patients undergoing prostatectomy for prostate cancer, retrospectively reviewing data over a 10 year period.

Overall comments:

1\. The authors were diligent with comparison between subtypes, including TNM classification and histology. Unfortunately this meant small groups for propensity matching which influences the rigorousness of their statistical significance.

2\. There was wide variability in the HR for overall survivability, but results were still meaningful.

3\. Their overall conclusion that results were significant but require further investigation is appropriate.

Recommendation: Accept with minor edits.

Copyedits:

1\. Abstract conclusion: Remove \"Besides\", substitute \"In addition,\".

2\. Introduction, page 9, line 6. Remove \"Besides,\"

3\. Introduction, page 9, Line 9-10, change to: Unfortunately, recurrence of prostate cancer in patients after surgery results in\...

4\. Introduction, page 9, line 10-11: change to \"Surgical intervention itself may result in neuroendocrine and metabolic changes which may lead to impaired cell-mediated immunity and activation of circulating tumor cell implantation.\"

5\. Introduction, page 9, line 15: Change to \"Research has shown that volatile anesthetics are pro-inflammatory\...\"

6\. Introduction, page 6, line 6: change to \"We hypothesized that patients under desflurane anesthesia may have poorer outcomes than patients under propofol\...\"

7\. In Methods section, page 11, same units should be used for flow: 300 mL/min

8\. Page 13, please change to: \"Because significant interactions with the two anesthetic techniques (propofol or desflurane) were found, we also performed subgroup analyses for TNM stage as well as postoperative BCR.\" Please add detail to statement: Because significant interactions with the two anesthetic techniques (propofol or desflurane) were found,

9\. page 14, end of page: \"This finding did not change substantially in the multivariable analyses after adjustment for those significant variables in the univariable analyses and 9 surgeons (HR, 0.12; 95% CI, 0.03--0.54; P = 0.006)\". Do you mean after adjustment for significant variables including the nine surgeons?

10\. page 15, \"After the multivariable analysis, a higher preoperative PSA level was another variable that was identified thatsignificantly increased the mortality risk.

11\. page 15, end of page: In summary, patients with desflurane anesthesia had more significant disease progression (such as postoperative BCR) than those with propofol anesthesia.

12\. Page 16, in discussion: \"The major findings in the present study are that propofol anesthesia in RARP improves survival and reduces postoperative BCR compared with desflurane anesthesia.The results were consistent with our previous reports demonstrating that propofol anesthesia\...\"

13\. Page 16, discussion: \"The result was consistent with Coughlin et al., who reported that\...\"

14\. Page 16, discussion: \"However, previous data indicated that considerable number of men had

prostate cancer despite being within normal PSA range. Importantly, many of these patients were later found to have high grade histology.\"

15\. Page 16, discussion, end of page: \"The perioperative stress induced by surgery leads to metabolic and neuroendocrine changes that result in significant depression of cell mediated immunity. This can result in the emergence of micro-seed tumor cells during surgery, which can avoid\...\"

16\. Page 17, discussion:\" In addition, HIF-1 was overexpressed in pancreatic cancer,32 and a knockout of HIF-1\...\"

17\. Page 18, discussion: \" However, the cancer-specific mortality was lower than previous reports (1.7% and 4.3%). This might be due to the higher surgical volume at our center and higher level of experience because we excluded patients from the learning curve period of the first two years of surgery performed by our teams.\"

18\. Page 19, discussion: \"We conducted the surgeon analysis (n=9) and

the result showed that, in our high volume surgery center, the postoperative outcome was not affected by which surgeon performed the procedure (Table 2). Finally, the anesthesiologists chose the type of anesthesia, which may have been subject to original selection bias\...\"

Reviewer \#2: This is a retrospective study in which the authors evaluate the effect of propofol vs desflurane anesthesia on survival. Propofol anesthesia improved overall survival in robot-assisted radical

prostatectomy compared with desflurane anesthesia. Furthermore, patients with propofol anesthesia had less postoperative biochemical recurrence.

This is an interesting study adding to literature that supports the beneficial effects of propofol on overall survival and cancer recurrence. However, I am concerned about the statistics. First of all the authors did not distinguish between mediators and confounders in their analysis, which means that thy might have over-adjusted. Second, I do not see any correction for multiple comparisons.

Specific comments

Abstract:

Methods: please specify the outcomes

Page 8: the authors use many abbreviations, which makes the manuscript hard to read

Introduction

Page 9, para 1: please change to: Unfortunately, recurrence of prostate cancer after surgery increases postoperative morbidity and mortality.

Page 9, para 1: which may impair cell-mediated............

Page 10 para 1: Please move the discussion in regards to neuraxial anesthesia to the discussion section. It inhibits the flow of the introduction.

Page 10, para 1, hypothesis: please be more specific. What is your primary and what is the secondary hypothesis?

Page 11, para 2: "The exclusion criteria were propofol anesthesia combined with VAs or regional analgesia" I assume that regional anesthesia was excluded for the desflurane patients as well?

Page 11, last para: did you really use 100% oxygen?

Page 12, para 2: "time since earliest included patient". What does that mean? Why did you not use "year of surgery"?

Page 13, para 1: you list many potential confounding factors. Please be careful in distinguishing whether these variables are true confounders or mediators. A confounder is associated with both the treatment as well as the outcome, while a mediator is associated with the outcome.

F.e Tumor staging is associated with the outcome (survival) but not with the treatment (propofol or desflurane anesthesia) and thus is a mediator for which you cannot adjust.

Page 13, para 2: The primary outcome was overall survival? Or was it time to death?

Page 13: the authors make several comparisons. How did you correct for multiple comparisons?

Page 14, para 3: "according to the anesthetic technique and other variables were compared individually in a" What are the other variables?

Table 1: Please use standardized difference for the matched variables (and not p-value)

Page 18, limitations: as you excluded patients with regional anesthesia your fith limitation is actually not a limitation.

Please be consistent with the tense (past or present) you use throughout the manuscript.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Dr.Zhi-Fu Wu

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Ehab Farag, MD FRCA FASA
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Dear Dr. Wu:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.
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PLOS ONE Editorial Office Staff
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Dr. Ehab Farag
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